Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.32|
|52 Week High||AU$0.10|
|52 Week Low||AU$0.48|
|1 Month Change||-10.00%|
|3 Month Change||57.50%|
|1 Year Change||80.00%|
|3 Year Change||28.57%|
|5 Year Change||57.50%|
|Change since IPO||-95.33%|
Recent News & Updates
Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Rhinomed...
Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|RNO||AU Pharmaceuticals||AU Market|
Return vs Industry: RNO exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: RNO exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: RNO is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 32% a week.
Volatility Over Time: RNO's weekly volatility has increased from 20% to 32% over the past year.
About the Company
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company’s product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.
Rhinomed Fundamentals Summary
|RNO fundamental statistics|
Is RNO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RNO income statement (TTM)|
|Cost of Revenue||AU$1.14m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.034|
|Net Profit Margin||-195.40%|
How did RNO perform over the long term?See historical performance and comparison
Is Rhinomed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RNO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RNO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RNO is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: RNO is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RNO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RNO is overvalued based on its PB Ratio (16.8x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Rhinomed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rhinomed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Rhinomed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RNO is currently unprofitable.
Growing Profit Margin: RNO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RNO is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare RNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: RNO has a negative Return on Equity (-181.34%), as it is currently unprofitable.
How is Rhinomed's financial position?
Financial Position Analysis
Short Term Liabilities: RNO's short term assets (A$3.8M) exceed its short term liabilities (A$1.4M).
Long Term Liabilities: RNO's short term assets (A$3.8M) exceed its long term liabilities (A$400.7K).
Debt to Equity History and Analysis
Debt Level: RNO is debt free.
Reducing Debt: RNO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RNO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RNO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.4% each year
What is Rhinomed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RNO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RNO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RNO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.63M) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
Experienced Board: RNO's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rhinomed Limited's employee growth, exchange listings and data sources
- Name: Rhinomed Limited
- Ticker: RNO
- Exchange: ASX
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$79.950m
- Shares outstanding: 253.81m
- Website: https://www.rhinomed.global
- Rhinomed Limited
- 132 Gwynne Street
- Level 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:28|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.